Ginkgo Bioworks Holdings Analyst Ratings
Ginkgo Bioworks Holdings Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/15/2023 | 59.59% | Raymond James | → $2.5 | Downgrades | Outperform → Market Perform |
11/14/2023 | 59.59% | Raymond James | → $2.5 | Downgrades | Outperform → Market Perform |
11/09/2023 | — | BTIG | Downgrades | Buy → Neutral | |
06/05/2023 | -20.2% | Goldman Sachs | $3 → $1.25 | Maintains | Sell |
06/02/2023 | -20.2% | Goldman Sachs | $3 → $1.25 | Downgrades | Neutral → Sell |
05/11/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
11/29/2022 | 283.02% | Berenberg | → $6 | Initiates Coverage On | → Buy |
10/04/2022 | 219.18% | Morgan Stanley | → $5 | Initiates Coverage On | → Equal-Weight |
08/16/2022 | 283.02% | BTIG | $5 → $6 | Maintains | Buy |
08/16/2022 | 825.63% | Raymond James | $11.5 → $14.5 | Maintains | Outperform |
06/16/2022 | 177.69% | Jefferies | $11.5 → $4.35 | Maintains | Buy |
05/18/2022 | 91.51% | B of A Securities | $6 → $3 | Downgrades | Neutral → Underperform |
03/02/2022 | 666.04% | Cowen & Co. | → $12 | Initiates Coverage On | → Outperform |
02/23/2022 | 346.86% | Goldman Sachs | → $7 | Initiates Coverage On | → Neutral |
02/01/2022 | 283.02% | B of A Securities | → $6 | Initiates Coverage On | → Neutral |
01/28/2022 | 410.69% | B of A Securities | → $8 | Initiates Coverage On | → Buy |
01/07/2022 | 666.04% | BTIG | → $12 | Initiates Coverage On | → Buy |
10/13/2021 | 825.63% | Raymond James | → $14.5 | Initiates Coverage On | → Outperform |
10/12/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
09/20/2021 | 793.71% | HSBC | → $14 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/15/2023 | 59.59% | 雷蒙德·詹姆 | → 2.5 美元 | 降级 | 跑赢大盘 → 市场表现 |
11/14/2023 | 59.59% | 雷蒙德·詹姆 | → 2.5 美元 | 降级 | 跑赢大盘 → 市场表现 |
11/09/2023 | — | BTIG | 降级 | 买入 → 中性 | |
06/05/2023 | -20.2% | 高盛 | 3 美元 → 1.25 美元 | 维护 | 卖出 |
06/02/2023 | -20.2% | 高盛 | 3 美元 → 1.25 美元 | 降级 | 中性 → 卖出 |
05/11/2023 | — | 威廉布莱尔 | 降级 | 跑赢大盘 → 市场表现 | |
2022 年 11 月 29 日 | 283.02% | 贝伦贝格 | → 6 美元 | 启动覆盖范围开启 | → 购买 |
2022 年 4 月 10 日 | 219.18% | 摩根士丹利 | → 5 美元 | 启动覆盖范围开启 | → 重量相等 |
08/16/2022 | 283.02% | BTIG | 5 美元 → 6 美元 | 维护 | 买 |
08/16/2022 | 825.63% | 雷蒙德·詹姆 | 11.5 美元 → 14.5 美元 | 维护 | 跑赢大盘 |
06/16/2022 | 177.69% | 杰富瑞集团 | 11.5 美元 → 4.35 美元 | 维护 | 买 |
05/18/2022 | 91.51% | B of A 类证券 | 6 美元 → 3 美元 | 降级 | 中性 → 跑赢大盘 |
03/02/2022 | 666.04% | Cowen & Co. | → 12 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
2022 年 2 月 23 日 | 346.86% | 高盛 | → 7 美元 | 启动覆盖范围开启 | → 中立 |
2022 年 1 月 2 日 | 283.02% | B of A 类证券 | → 6 美元 | 启动覆盖范围开启 | → 中立 |
01/28/2022 | 410.69% | B of A 类证券 | → 8 美元 | 启动覆盖范围开启 | → 购买 |
2022 年 7 月 1 日 | 666.04% | BTIG | → 12 美元 | 启动覆盖范围开启 | → 购买 |
2021 年 10 月 13 日 | 825.63% | 雷蒙德·詹姆 | → 14.5 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
2021 年 12 月 10 日 | — | 威廉布莱尔 | 启动覆盖范围开启 | → 跑赢大盘 | |
09/20/2021 | 793.71% | 汇丰银行 | → 14 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Ginkgo Bioworks Holdings (DNA)?
银杏生物工程控股公司(DNA)的目标价格是多少?
The latest price target for Ginkgo Bioworks Holdings (NYSE: DNA) was reported by Raymond James on November 15, 2023. The analyst firm set a price target for $2.50 expecting DNA to rise to within 12 months (a possible 59.59% upside). 7 analyst firms have reported ratings in the last year.
雷蒙德·詹姆斯于2023年11月15日公布了银杏生物工程控股公司(纽约证券交易所代码:DNA)的最新目标股价。该分析公司将目标股价定为2.50美元,预计DNA将在12个月内升至12个月内(可能上涨59.59%)。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Ginkgo Bioworks Holdings (DNA)?
Ginkgo Bioworks Holdings(DNA)的最新分析师评级是多少?
The latest analyst rating for Ginkgo Bioworks Holdings (NYSE: DNA) was provided by Raymond James, and Ginkgo Bioworks Holdings downgraded their market perform rating.
雷蒙德·詹姆斯对银杏生物工程控股公司(纽约证券交易所代码:DNA)的最新分析师评级由雷蒙德·詹姆斯提供,银杏生物工程控股下调了其市场表现评级。
When is the next analyst rating going to be posted or updated for Ginkgo Bioworks Holdings (DNA)?
Ginkgo Bioworks Holdings(DNA)的下一次分析师评级何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ginkgo Bioworks Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ginkgo Bioworks Holdings was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Ginkgo Bioworks Holdings的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Ginkgo Bioworks Holdings的最新评级是在2023年11月15日公布的,因此您应该预计下一个评级将在2024年11月15日左右公布。
Is the Analyst Rating Ginkgo Bioworks Holdings (DNA) correct?
分析师对银杏生物工程控股公司(DNA)的评级是否正确?
While ratings are subjective and will change, the latest Ginkgo Bioworks Holdings (DNA) rating was a downgraded with a price target of $0.00 to $2.50. The current price Ginkgo Bioworks Holdings (DNA) is trading at is $1.57, which is within the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的Ginkgo Bioworks Holdings(DNA)评级已下调,目标股价为0.00美元,至2.50美元。Ginkgo Bioworks Holdings(DNA)的当前交易价格为1.57美元,在分析师的预测区间内。